After discussions with the FDA, Oncopeptides AB has initiated the preparation for submitting a New Drug Application for accelerated approval of melflufen for the treatment of patients with triple-class refractory multiple myeloma.
FDA has approved Venclexta (venetoclax) in combination with obinutuzumab (Gazyva) for previously untreated patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.
FDA approved Cyramza (ramucirumab), sponsored by Eli Lilly, as a single agent for hepatocellular carcinoma in patients who have an alpha fetoprotein of ≥ 400 ng/mL and have been previously treated with sorafenib.
FDA has approved Bavencio (avelumab) in combination with Inlyta (axitinib) for the first-line treatment of patients with advanced renal cell carcinoma.
GE Healthcare and Indi Molecular Inc. announced plans to develop immune cell-targeted Positron-Emission Tomography tracer candidates, based on Indi Molecular's proprietary Protein Catalyzed Capture technology.
FDA has approved Genentech's Kadcyla (ado-trastuzumab emtansine) for adjuvant treatment of people with HER2-positive early breast cancer who have residual invasive disease after neoadjuvant taxane and Herceptin (trastuzumab)-based treatment.
FDA has granted Breakthrough Device designation to Natera Inc.'s Signatera test for use in the post-surgical detection and quantification of circulating tumor DNA in the blood of patients previously diagnosed with certain types of cancer and in combination with certain drugs. The designation will help accelerate FDA assessment and review of Signatera as an in vitro diagnostic for use in pharmaceutical trials.
FDA has granted Breakthrough Device designation for MI Transcriptome companion diagnostic test.
The European Commission has granted conditional marketing authorization to Pfizer Inc. for Lorviqua (lorlatinib, available in the U.S., Canada, and Japan under the brand name Lorbrena), as a monotherapy for the treatment of adult patients with anaplastic lymphoma kinase-positive advanced non-small cell lung cancer whose disease has progressed after alectinib or ceritinib as the first ALK tyrosine kinase inhibitor therapy, or crizotinib and at least one other ALK TKI.
Arcus Biosciences Inc. and Strata Oncology Inc. entered into a clinical development collaboration utilizing Strata's precision drug development platform and proprietary biomarkers to evaluate AB122, Arcus's clinical-stage anti-PD-1 antibody, in a basket trial including tumor types that are generally not responsive to anti-PD-1 therapy.
